Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib Neoadjuvant Therapy for ALK+ NSCLC
NCT06779539Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological Complete Response Rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06779539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06779539.